Basit öğe kaydını göster

dc.contributor.authorCömez, Birnur
dc.contributor.authorAkbuğa, Jülide
dc.date.accessioned2023-07-27T08:28:14Z
dc.date.available2023-07-27T08:28:14Z
dc.date.issued2023en_US
dc.identifier.citationCömez, B. ve Akbuğa, J. (2023). Effects of chitosan nanoparticles with long synthetic siRNAs targeting VEGF in triple-negative breast cancer cells. Brazilian Journal of Pharmaceutical Sciences, 59. https://dx.doi.org/10.1590/s2175-97902023e22304en_US
dc.identifier.issn1984-8250
dc.identifier.issn2175-9790
dc.identifier.urihttps://dx.doi.org/10.1590/s2175-97902023e22304
dc.identifier.urihttps://hdl.handle.net/20.500.12511/11266
dc.description.abstractVascular endothelial growth factor (VEGF) is an essential angiogenic factor in breast cancer development and metastasis. Small interfering RNAs (siRNAs) can specifically silence genes via the RNA interference pathway, therefore were investigated as cancer therapeutics. In this study, we investigated the effects of siRNAs longer than 30 base pairs (bp) loaded into chitosan nanoparticles in triple-negative breast cancer cells, compared with conventional siRNAs. 35 bp long synthetic siRNAs inhibited VEGF gene expression by 51.2% and increased apoptosis level by 1.75-fold in MDA-MB-231 cell lines. Furthermore, blank and siRNA-loaded chitosan nanoparticles induced expression of IFN-γ in breast cancer cells. These results suggest that long synthetic siRNAs can be as effective as conventional siRNAs, when introduced into cells with chitosan nanoparticles.en_US
dc.description.sponsorshipMarmara Universityen_US
dc.language.isoengen_US
dc.publisherFaculdade de Ciencias Farmaceuticas (Biblioteca)en_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.rightsAttribution 4.0 International*
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/*
dc.subjectBreast Canceren_US
dc.subjectChitosanen_US
dc.subjectNanoparticleen_US
dc.subjectsiRNAen_US
dc.subjectVEGFen_US
dc.titleEffects of chitosan nanoparticles with long synthetic siRNAs targeting VEGF in triple-negative breast cancer cellsen_US
dc.typearticleen_US
dc.relation.ispartofBrazilian Journal of Pharmaceutical Sciencesen_US
dc.departmentİstanbul Medipol Üniversitesi, Eczacılık Fakültesi, Eczacılık Teknolojisi Bölümü, Farmasötik Teknoloji Ana Bilim Dalıen_US
dc.authorid0000-0002-1693-9579en_US
dc.identifier.volume59en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.identifier.doi10.1590/s2175-97902023e22304en_US
dc.institutionauthorAkbuğa, Jülide
dc.identifier.wosqualityQ4en_US
dc.identifier.wos001020586300001en_US
dc.identifier.scopus2-s2.0-85163849381en_US
dc.identifier.scopusqualityQ2en_US


Bu öğenin dosyaları:

Thumbnail

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster

info:eu-repo/semantics/openAccess
Aksi belirtilmediği sürece bu öğenin lisansı: info:eu-repo/semantics/openAccess